Increased vascular permeability after cardiopulmonary bypass in patients with diabetes is associated with increased expression of vascular endothelial growth factor and hepatocyte growth factor  by Emani, Sirisha et al.
Emani et al Perioperative ManagementIncreased vascular permeability after cardiopulmonary bypass in
patients with diabetes is associated with increased expression of
vascular endothelial growth factor and hepatocyte growth factor
Sirisha Emani, PhD, Basel Ramlawi, MD, Neel R. Sodha, MD, Jian Li, MD, PhD,
Cesario Bianchi, MD, PhD, and Frank W. Sellke, MD
Background: Several inflammatory mediators such as vascular endothelial growth factor and hepatocyte growth
factor are known to play a critical role in the regulation of vascular permeability and angiogenesis. We studied
the serum levels of growth factors and gene expression profiles of genes involved in growth factor signaling
in the peripheral blood of patients with and patients without diabetes following cardiopulmonary bypass and
cardioplegic arrest.
Methods: Serum and total RNA were obtained from the blood samples collected from patients with diabetes and
matched patients without diabetes (n ¼ 7 patients each) who had coronary artery bypass graft before and 6 hours
and 4 days after cardiopulmonary bypass/cardioplegic arrest. The cytokine panel, consisting of growth factors
such as vascular endothelial growth factor, hepatocyte growth factor, fibroblast growth factor, and epidermal
growth factor, was quantified in patients with diabetes and patients without diabetes before and 6 hours and 4
days post–cardiopulmonary bypass/cardioplegic arrest using multiplex cytokine quantification system. cDNA
microarray analysis was performed and fold-change was calculated.
Results: Length of hospitalization (10 vs 6 days; P ¼ .04) and weight gain (5 vs 2.5 kg; P ¼ .001) were signif-
icantly greater for patients with diabetes compared with patients without diabetes. The serum levels of vascular
endothelial growth factor and hepatocyte growth factor were significantly elevated in patients with diabetes when
compared with patients without diabetes before versus 6 hours post–cardiopulmonary bypass/cardioplegic arrest.
In addition, significantly elevated mRNA expression of hypoxia-inducible factor-1a, cyclic adenosine mono-
phosphate response element binding protein, and E1A binding protein p300 (more than twofold) was observed
4 days post–cardiopulmonary bypass/cardioplegic arrest exclusively in patients with diabetes.
Conclusions: The differential profile of gene and protein expression of growth factors and their related genes in
patients with diabetes and patients without diabetes could be associated with increased edema and weight gain in
patients with diabetes after cardiopulmonary bypass/cardioplegic arrest.P
MCardiovascular disease is the leading cause of death among
individuals with diabetes mellitus (DM), and  34% of the
patients having coronary artery bypass grafting (CABG)
have been reported to have diabetes.1 Several adverse surgi-
cal outcomes, such as higher perioperative mortality, sternal
wound infections, postoperative stroke, and longer hospital-
ization post–cardiac surgery, have been reported in patients
with DM compared with patients without DM.2,3
Cardiopulmonary bypass (CPB) during cardiac surgery is
associated with extensive inflammatory triggers including
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doi:10.1016/j.jtcvs.2008.12.024The Journal of Thoracic and Cthe blood-bypass circuit interface, ischemia–reperfusion in-
jury of heart and lungs, and operative trauma. These inflam-
matory signals induce the activation of microcirculation
throughout the body, thus leading to multiorgan dysfunction
in the immediate postoperative period.4 The other major con-
tributory factor for organ dysfunction after CPB is postoper-
ative hypoxia.
Hypoxic conditions can induce a variety of genes encoding
proteins including growth factors, such as vascular endothelial
growth factor (VEGF), via hypoxia-inducible factor-1a
(HIF-1a), which regulates vascular permeability and cell pro-
liferation.5 Growth factors such as insulin-like growth factor,6
hepatocyte growth factor (HGF),7 keratocyte growth factor,8
transforming growth factor-b1,9 and also the inflammatory
mediators including interleukin-1 and interleukin-610 are
known to regulate VEGF synthesis. VEGF is a multifunc-
tional cytokine, overexpressed in hypoxia, and is known to
be involved in wound healing,11 formation of collateral
vessels in ischemic tissue,12 chronic inflammatory disorders
(psoriasis, rheumatoid arthritis),13 diabetic retinopathy,14
and tumor growth.15 The biologic properties ofVEGF includeardiovascular Surgery c Volume 138, Number 1 185
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CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
CREB ¼ cyclic adenosine monophosphate
response element binding protein
CRP ¼ C-reactive protein
DM ¼ diabetes mellitus
EP300 ¼ E1A binding protein p300
HGF ¼ hepatocyte growth factor
HIF-1a ¼ hypoxia-inducible factor-1a
PCR ¼ polymerase chain reaction
RMA ¼ Robust Multichip average
VEGF ¼ vascular endothelial growth factor
endothelial cell proliferation,16 chemotaxis of macrophages
and vascular smooth muscle cells,17 induction of adhesion
molecules (vascular cell adhesion molecule and intercellular
adhesion molecule),18 and metalloproteinase synthesis.19
On the other hand, C-reactive protein (CRP), a potential
marker for acute inflammation and a potent independent pre-
dictor for cardiovascular diseases including arteriosclero-
sis,20 has been reported to down-regulate VEGF receptors
on endothelial cells21 and thus may lead to decreased angio-
genesis in patients with DM. Acute systemic hypoxia can
induce leukocyte extravasation into tissues via VEGF sig-
naling followed by fluid accumulation and thus induces
overall weight gain in patients after cardiac surgery.
Themechanisms contributing to the differences in the post-
surgical complications observed between patients with DM
and patients without DM are not well established. In this
study, we evaluated serum levels of several growth factors in-
cludingVEGFandHGF aswell as gene expression profiles of
genes involved in growth factor signaling in the peripheral
blood of patientswithDMandpatientswithoutDMfollowing
CPB/cardioplegic arrest. The observed differential quantita-
tive and qualitative protein and gene expressions between pa-
tientswithDMandpatientswithoutDMcouldprovide insight
into the observed differences in postoperative inflammatory
state between the 2 patient populations.
MATERIALS AND METHODS
Subjects
This prospective cohort study was initiated after being approved by the
Beth Israel Deaconess Medical Center Institutional Review Board/Commit-
tee on Clinical Investigations. Before enrollment, informed written consent
was obtained from all patients interested in participating in the study. The 14
enrolled patients were scheduled for either elective or urgent primary CABG
or valvular surgery (aortic, mitral, or both). Because all patients with DM
considered for the study had elevated preoperative blood sugar levels
 240 mg/dL, they had preoperative treatment using either an insulin
infusion or subcutaneous treatment. Normoglycemic patients without DM
received no further glucose treatment presurgery.186 The Journal of Thoracic and Cardiovascular SuAnesthetic And Surgical Technique
Under general anesthesia, midline sternotomy was performed, and sys-
temic heparin (100 U/kg) was administered to attain an activated clotting
time> 400. The right atrium and ascending aorta were cannulated, and
CPB was initiated. CPB circuit consisted of a standard roller pump, a mem-
brane oxygenator, and a 40-mm arterial filter. The circuit was primed with
crystalloid solution. CPB strategy included the use of mild hypothermia
(30C–34C), maintenance of serum glucose levels  130 mg/dL with in-
travenous insulin injections, and a-stat pH monitoring. During CPB, insu-
lin infusion was utilized to maintain normoglycemia, and this strategy was
continued in the intensive care unit for 24 hours. Subsequently, subcutane-
ous insulin was utilized for postoperative glucose control. Pump blood
flow was maintained between 2 and 2.4 L $ min1 $ m2 of body surface
area, and mean arterial pressure was maintained between 50 and 90 mm
Hg with the use of conventional vasoactive medications. Cell-Saver
(Haemonetics Corp., Braintree, Mass) and cardiotomy suction were uti-
lized. The decision to administer antifibrinolytic agents (either aprotinin
or Amicar) was left to the discretion of the operating team. Cardiac arrest
was induced and maintained with antegrade administration of cold-blood
hyperkalemic (25 mmol/L) cardioplegic solution.
Blood Processing and RNA Extraction
Blood samples were collected in the sterile PAX tubes (Qiagen Inc,
Valencia, Calif) from the central venous line after induction of anesthesia
but before skin incision preoperatively and 6 hours and 4 days post–CPB/
cardioplegic arrest. Blood samples were centrifuged immediately at
15,000g for 15 minutes, and serum/plasma samples were frozen at80C
until the time of the assay. RNA extraction was performed using PAX
gene kit (Qiagen Inc). For microarray analysis, after the quantitative and
qualitative assessment of extracted total RNA, single-stranded followed
by double-stranded cDNA synthesis was performed. Biotin-labeled cRNA
was obtained by in vitro transcription of double-stranded cDNA using
AFFI kit (Affymetrix, Santa Clara, Calif). cRNA was further purified, frag-
mented, hybridized overnight onto Affymetrix gene chips, washed in strep-
tavidin followed by array scanning as previously described.22
Microarray Analysis
Transcriptional profilingwas performed onHG-U133 plus 2.0 Affymetrix
chips containing>47,000 transcripts. The quality of the chips was assessed,
and the outliers, calculated using the dChip algorithm, were eliminated from
the analysis. Matrix of gene expression values was generated using Robust
Multichip average (RMA) normalization statistics (John’s Hopkins Univer-
sity, Baltimore, Md). The presence calls of transcripts obtained from Micro-
array system 5 in conjunction with gene expression values from RMA were
used to generate a fusion model to compare the differences in gene regulation
postsurgery (6 hours or 4 days) comparedwith pre–cardiac surgery in patients
with DM versus patients without DM (n ¼ 7 each group). Changes of more
than twofold along with enhanced expression of that transcript in 50% or
more of patients post–cardiac surgery for up-regulated genes or presurgery
for down-regulated genes were the major criteria to determine significant dif-
ferential gene regulation between the subsets (P< .001).
Real-Time Polymerase Chain Reaction
For real-time polymerase chain reaction (PCR) analysis, one-step reverse
transcriptase–PCR reactions were performed using SYBR Green detection
in the final volume of 25 mL. The specific primers for the genes of interest
were designed using OligoPerfect software (Invitrogen Inc, Carlsbad,
Calif). SYBRGreen reactions were performed with SYBRGreen PCRMas-
ter Mix (Applied Biosystems, Foster City, Calif) with added reverse tran-
scriptase and RNAase inhibitor using ABI Prism 7000 Sequence detector
system (Applied Biosystems). The following conditions were used to run
the reaction: 30 minutes at 48C, 10minutes at 95C for 1 cycle, and 15 sec-
onds at 95C and 1 minute at 60C for 40 cycles. Relative expression levels
of the genes were analyzed using 2-ddCT method in comparison to thergery c July 2009
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ple was analyzed in duplicates.
Multiplex Florescent-Bead Immunoassay
Amultiplex florescent-bead immunoassay was performed to detect cyto-
kine concentrations from the serum samples (n ¼ 7 each, patients with DM
and patients without DM) diluted 1:1 in buffer provided with the kit (Invi-
trogen). Cytokines were analyzed in duplicates. Standard curves were gen-
erated for each cytokine by using the reference cytokine concentrations
supplied by the manufacturer. Raw data (mean fluorescent intensity) were
analyzed by Beadview Software (Upstate Inc, Charlottesville, Va) to obtain
concentration values.
Statistical Analysis
RMA statistical software was used to calculate fold-change for analyzing
differential gene expression by microarray. For cytokine comparison
analysis, one-way analysis of variance in combination with standard t test
(SYSTAT Software Inc., San Jose, Calif) was used to calculate significance.
RESULTS
Clinical Characteristics and Outcomes
There were no other significant differences between
patients with DM and patients without DM in terms of
demographics and perioperative data except for diabetes,
hyperglycemia, and hemoglobin A1C (P< .001; Table 1).
All patients in the study had successful cardiac surgery
and recovery (no reoperations or deaths). Clinical outcomes
showed significant differences for length of hospital stay
post–CPB/cardioplegic arrest (P ¼ .04) and weight gain
(P¼ .001) but not for atrial fibrillation and sternal wound in-
fections between the 2 patient populations (Table 1). No sta-
tistically significant difference in postoperative diuretic,
blood product, or intravenous fluid administration was
detected between the groups. However, the average fluid
balance on the day of surgery was 3562  725.1 and 3582
 1042 (P ¼ .99) and on postoperative day 4 wasþ600 
1027.8 and108 903.2 (P ¼ .6), respectively, for patients
with DM versus patients without DM. The fluid balance is
a crude estimate of fluid homeostasis as the exact measure-
ment of fluid gain and loss through bowel movements, food
intake, and insensible losses is difficult, and weight gain
more accurately represents the cumulative fluid retention.
VEGF Expression
VEGF, a multifunctional cytokine known to be involved in
inflammatory responses andweight gain, was significantly in-
creased following CPB when measured at 6 hours post–CPB/
cardioplegic arrest only in patients with DM (P < .05).
The expression of VEGF tended to be higher even after 4
days postsurgery when compared with presurgery only in pa-
tients with DM, but this difference was not significant. In the
case of patients without DM, the variations in VEGF expres-
sion at 6 hours or 4 days post–CPB/cardioplegic arrest com-
pared with presurgery were minimal (Figure 1, A). The
relative difference inVEGF expression (presurgery vs 6 hours
post–CPB/cardioplegic arrest) was significantly higher inThe Journal of Thoracic and Cpatients with DM when compared with patients without DM
(P< .02). There was a trend toward higher relative rise of
VEGFexpressionevenat 4 dayspost–CPB/cardioplegic arrest
in patients with DM compared with patients without DM, but
this trend was not statistically significant (Figure 1, B).
HGF Expression
HGF, another multifunctional cytokine known to be in-
volved in inflammation and hypervascular permeability,
was enhanced significantly 6 hours post–CPB/cardioplegic
arrest in both patients with DM and patients without DM
(P< .05). Also, the expression levels were significantly
higher (P< .01) in patients with DM as compared with pa-
tients without DM 6 hours post–CPB/cardioplegic arrest.
The expression of HGF tended to be higher than presurgery
levels even at 4 days post–CPB/cardioplegic arrest in both
the patient populations but with no statistical significance
(Figure 2, A). Similar to VEGF expression, the relative dif-
ference in HGF expression (presurgery vs 6 hours post–
CPB/cardioplegic arrest) was significantly higher in patients
with DM (P< .02) compared with patients without DM
(Figure 2, B). The relative rise between patients with DM
TABLE 1. Patient characteristics
Characteristics DM ND P value
Age (y)* 62.4  2.1 67.7  3.2 .2
Men/women (n) 4/3 6/1 .4
HbA1C (mg/dL)* 12  1.4 5.6  0.3 <.001
Blood glucose levels (mg/dL)* 292.9  21.9 119  12.8 <.001
Obesity (BMI>30) 3/7 (42.8%) 4/7 (57.1%) .7
History of
hypercholesterolemia
with/without treatment (n)
7 (100%) 5 (71%) .4
Hypertension on admission (n) 2 (28.5%) 1 (14.3%) .7
Chronic renal insufficiency
(creatinine>2), n
1 (14.3%) 1 (14.3%) NS
Aminocaproic acid
(Amicar, 100 mg/kg
load, 5-g pump prime,
30 mg $ kg1 $ h1 infusion)
4 4 NS
Aprotinin
(half-Hammersmith
dose at 1,000,000 KIU)
3 3 NS
CABG only (n) 5 5 NS
No. of grafts performed (n) 3 3 NS
CABGþvalve procedures (n) 2 2 NS
Crossclamp time (min)* 64.3  17.6 54  8.7 .6
Duration of CPB (min)* 98.7  17.3 73.7  8.9 .2
Atrial fibrillation (n) 2 (28.5%) 2 (28.5%) NS
Length of stay post surgery (d)* 10  1 6  0.4 .04
Weight gain 1 d post-CPB (kg)* 6.4  1.2 6.5  1.5 .8
Weight gain 4 days post-CPB (kg)* 5  0.5 2.5  0.4 .001
Intraoperative insulin (U/h)* 7 0 .009
Postoperative insulin (U/h)* 4 3 .04
BMI, Body mass index; CABG, coronary artery bypass grafting; CPB, cardiopulmo-
nary bypass; HbA1C, hemoglobin A1C; NS, no significance. *Data expressed as
mean  standard error of the mean.ardiovascular Surgery c Volume 138, Number 1 187
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line levels when assessed at 4 days post–CPB/cardioplegic
arrest (Figure 2, B). No significant differences in expression
of other growth factors, such as epidermal growth factor and
fibroblast growth factor, were observed between patients
with DM and patients without DM at all time points tested
presurgery compared with post-CPB (data not shown).
Hypoxia Signaling Pathway
In correlation with VEGF and HGF expression, HIF-1a,
a crucial regulator of hypoxia signaling, and other HIF-1a-
FIGURE 1. Vascular endothelial growth factor (VEGF) cytokine expres-
sion in patients with diabetes mellitus (DM) and patients without diabetes
mellitus (ND) presurgery (pre), 6 hours postsurgery (6h), and 4 days postsur-
gery (4d).A, VEGF concentrations (pg/mL) in the serum of patients with di-
abetes mellitus and patients without diabetes mellitus (n ¼ 7 each) at the
indicated time points. *P<.05 in cytokine expression presurgery compared
with 6 hours or 4 days for the specific population (patients with diabetesmel-
litus or patients without diabetes mellitus). B, Relative VEGF concentration
presurgery comparedwith 6 hours or 4 days postsurgery. *P<.05 in relative
cytokine expression in patientswith diabetesmellitus versus patientswithout
diabetes mellitus at that time point. Closed squares, Presurgery in patients
with diabetes mellitus; closed triangles, 6 hours postsurgery in patients
with diabetes mellitus; closed circles, 4 days postsurgery in patients with di-
abetes mellitus; open squares, presurgery in patients without diabetes melli-
tus; open triangles, 6 hours postsurgery in patients without diabetesmellitus;
and open circles, 4 days postsurgery in patients without diabetes mellitus.188 The Journal of Thoracic and Cardiovascular Surelated transcription factors such as E1A binding protein
p300 (EP300) and cyclic adenosine monophosphate re-
sponse element binding protein (CREB) were significantly
up-regulated greater than twofold only in patients with DM
(P< .001) 4 days post–CPB/cardioplegic arrest (Figure 3).
Validation of these exclusively up-regulated genes in pa-
tients with DM involved in hypoxia signaling pathway
FIGURE 2. Hepatocyte growth factor (HGF) cytokine expression in pa-
tients with diabetes mellitus (DM) and patients without diabetes mellitus
(ND) presurgery (pre), 6 hours postsurgery (6h), and 4 days postsurgery
(4d). A, HGF concentrations (pg/mL) in the serum of patients with diabetes
mellitus and patients without diabetes mellitus (n ¼ 7 each) at the indicated
time points. *P< .05 in cytokine expression presurgery compared with 6
hours or 4 days postsurgery for the specific population (patients with diabe-
tes mellitus or patients without diabetes mellitus). **P< .05 in concentra-
tion of HGF in patients with diabetes mellitus versus patients without
diabetes mellitus at that time. B, Relative HGF concentration presurgery
compared with 6 hours or 4 days postsurgery. *P<.05 in the relative cyto-
kine expression in patients with diabetes mellitus versus patients without di-
abetes mellitus at that time. Closed squares, presurgery in patients with
diabetes mellitus; closed triangles, 6 hours postsurgery in patients with di-
abetes mellitus; closed circles, 4 days postsurgery in patients with diabetes
mellitus; open squares, presurgery in patients without diabetes mellitus;
open triangles, 6 hours postsurgery patients without diabetes mellitus;
and open circles, 4 days postsurgery patients without diabetes mellitus.rgery c July 2009
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ure 4). In contrast, the above hypoxia-related genes were not
up- or down-regulated in patients without DM. The genes in-
volved in downstream VEGF signaling such as KRAS and
SOS were also significantly up-regulated only in patients
with DM (data not shown). SHC, an adaptor protein known
to mediate HIF-1a induction under hypoxic conditions, was
down-regulated only in patients without DM (data not
shown). Insulin-like growth factor 1 receptor (IGF1R) was
significantly expressed exclusively in patients with DM
(P< .001) 4 days post-CPB (data not shown).
Correlation between Serum VEGF Levels and CRP
CRP, a marker of acute inflammation and a contributor to
inflammatory diseases including arteriosclerosis as well as
FIGURE3. Hypoxia signaling pathway in patients with diabetesmellitus 4
days post–cardiopulmonary bypass/cardioplegic arrest. Dark gray indicates
up-regulated genes, and light gray represents down-regulated genes in
patients with diabetes mellitus. None of the genes in this pathway were
up- or down- regulated in patients without diabetes mellitus at 4 days
post–cardiopulmonary bypass/cardioplegic arrest. Data were analyzed
through the use of Ingenuity Pathway analysis (Ingenuity Systems, www.
ingenuity.com).The Journal of Thoracic and Cother cardiovascular diseases, was elevated to different
levels post-CPB in patients with DM and patients without
DM. CRP expression was significantly increased following
CPB when measured at 6 hours post–CPB/cardioplegic ar-
rest only in patients with DM (P<.05; Figure 5, A). The rel-
ative expression of CRP was significantly higher in patients
with DM when compared with patients without DM at 6
hours post–CPB/cardioplegic arrest (Figure 5, B). CRP
serum levels persistently increased post–CPB/cardioplegic
arrest and were significantly enhanced at 4 days in both
patients with DM and patients without DM (Figure 5). No
positive correlation was observed between VEGF and
CRP at any tested time in both the patient populations.
DISCUSSION
In this study, the serum VEGF levels increased signifi-
cantly in patients with DM compared with patients without
DM at 6 hours post–CPB/cardioplegic arrest. Furthermore,
the relative increase in VEGF and HGF levels presurgery
versus 6 hours post–CPB/cardioplegic arrest was signifi-
cantly higher in patients with DM when compared with
patients without DM. The results of the current study are pri-
marily a reflection of patients with poorly controlled diabe-
tes, and further investigation is required to extend the results
of this study to patients with better preoperative glucose
control.
Although the levels of VEGF were not significantly dif-
ferent between presurgery and 4 days post–cardiac surgery,
a trend toward higher VEGF levels was observed at least un-
til 4 days post–CPB/cardioplegic arrest in patients with DM.
Several studies reported up-regulation of VEGF and HGF
expression under hypoxic conditions in many disease set-
tings including diabetic retinopathy.7 HGF is also known
to function as a potent inducer of VEGF expression by
human epidermal keratinocytes23 and its receptor flk1 in
endothelial cells.24 VEGF and HGF growth factors were
extensively studied in relation to diabetic retinopathy and
are reported as major contributors to retinal edema.
FIGURE 4. Validation and comparison of up-regulated genes (exclusively
in patients with diabetes mellitus) in the hypoxia-signaling pathway using
quantitative real-time polymerase chain reaction versus microarray analysis.
*P< .001 between patients with diabetes mellitus versus patients without
diabetes mellitus.DM, Patients with diabetes mellitus; ND, patients without
diabetes mellitus.ardiovascular Surgery c Volume 138, Number 1 189
P
M
Perioperative Management Emani et alVEGF is a multifunctional cytokine known to be involved
in endothelial cell proliferation,16 chemotaxis of macro-
phages and vascular smooth muscle cells,17 and induction
of adhesion molecules (vascular cell adhesion molecule
and intercellular adhesion molecule)18 and metalloprotei-
nase synthesis.19 Acute systemic hypoxia can induce
VEGF expression, which regulates leukocyte extravasation
into tissues followed by fluid accumulation and thus induces
FIGURE 5. C-reactive protein (CRP) cytokine expression profile in pa-
tients with diabetes mellitus (DM) and patients without diabetes mellitus
(ND) presurgery (pre), 6 hours postsurgery (6h), and 4 days postsurgery
(4d). A, CRP concentrations (pg/mL) in the serum of patients with diabetes
mellitus and patients without diabetes mellitus (n ¼ 7 each) at the indicated
time points. *P< .05 in cytokine expression presurgery compared with 6
hours or 4 days postsurgery for the specific population (patients with diabe-
tes mellitus or patients without diabetes mellitus). B, Relative CRP concen-
tration presurgery compared with 6 hours or 4 days postsurgery. *P<.05 in
relative cytokine expression in patients with diabetes mellitus versus
patients without diabetes mellitus at that time point.Closed squares, Presur-
gery in patients with diabetes mellitus; closed triangles, 6 hours postsurgery
in patients with diabetes mellitus; closed circles, 4 days postsurgery in pa-
tients with diabetes mellitus; open squares, presurgery in patients without
diabetes mellitus; open triangles, 6 hours postsurgery in patients without dia-
betes mellitus; and open circles, 4 days postsurgery in patients without
diabetes mellitus.190 The Journal of Thoracic and Cardiovascular Suoverall weight gain in patients after cardiac surgery. In this
study, clinical outcomes such as length of hospitalization
(10 vs 6 days postsurgery; P ¼ .04) and weight gain (5 vs
2.5 kg 4 days postsurgery; P ¼ .001) were significantly
greater for patients with DM compared with patients without
DM, which may be a consequence of higher and sustained
VEGF serum levels in the DM population. Preoperative glu-
cose control and/or restoration to a normal hemoglobin A1C
may ameliorate the effects of CPB upon postoperative
recovery. In conjunction with VEGF protein expression
levels, CRP, a well-studied marker for systemic inflamma-
tion, was also expressed at higher levels in patients with
DM compared with patients without DM. CRP could serve
as another potential marker for weight gain in patients
with DM. Consideration must be given to strategies that re-
duce the inflammatory response in diabetic patients having
cardiac surgery. Such strategies include pharmacologic ma-
nipulation and performance of off-pump coronary bypass in
appropriate patients.
In correlation with VEGF cytokine levels, HIF-1a, a cru-
cial regulator of hypoxia signaling pathway and thus a potent
stimulator of VEGF, was significantly increased only in pa-
tients with DM 4 days post–CPB/cardioplegic arrest. CREB
and EP300, which act as coactivators of HIF-1a, were also
significantly expressed only in patients with DM 4 days
post–CPB/cardioplegic arrest. UBE2, a ubiquitin protein
known to catalyze hydroxylated human HIF-1a protein
and other ubiquitin proteins (Ub), was up-regulated only
in patients with DM.25 Some of the crucial genes that are in-
volved in the downstream signaling of VEGF such as KRAS
and its activator gene, SOS, were also up-regulated only in
patients with DM 4 days post–CPB/cardioplegic arrest.
VEGF signaling induces several genes including VEGF,
which acts in an autocrine manner.26 In contrast, the genes
regulated in patients without DM (such as SHC and
PKHR) were down-regulated, thus negatively impacting
the VEGF signaling pathway. Taken together, patients
with DM had an overall increase in regulation of the HIF-
1a pathway at multiple levels.
In addition, IGF1R, which is known to induce VEGF ex-
pression by positively regulating HIF-1a expression, was
also significantly expressed only in patients with DM 4
days post–CPB/cardioplegic arrest.27 Therefore, the differ-
ential expression of growth factors and their signaling re-
lated genes between patients with DM versus patients
without DM could contribute to the difference in observed
clinical outcomes in the 2 patient populations.
There are some limitations to our study. First, the study
was performed with few patient samples from each group
(patients with DM and patients without DM, n ¼ 7 each).
Based upon an effect size of 1.2 and power of 0.8, we esti-
mated a sample size of 12 in each group. However, given
the large differences noted between the diabetic versus non-
diabetic groups, the differences between the 2 groups werergery c July 2009
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underpowered to detect an effect size less than 1.5. Second,
more time points need to be analyzed to get a better under-
standing of growth factor functions post–cardiac surgery
in patients with DM and patients without DM. Previous
studies suggest a peak regulation of several inflammatory
and apoptotic genes within 6 hours post-CPB. Therefore, 6
hours postsurgery was considered as a time point of interest.
Because the inflammatory response is expected to abate by 4
days postsurgery, gene regulation was assessed at 4 days
post-CPB. Another limitation of the study is that although
there was no significant difference in the duration of CPB
between patients with DM and patients without DM, there
was a trend toward longer bypass time in the patients with
DM.
Although our study implies the possibility that VEGF
may have some role in developing edema and fluid retention
in patients with DM, it could be difficult to predict if in-
creases in plasma VEGF adversely influence weight gain
in patients with DM or could be useful for therapeutic angio-
genesis for ischemic artery disease, which is often seen in
patients with type 2 diabetes.28 However, the systemic
edema and weight gain may partially be attributed to
VEGF function along with the expression of other inflam-
matory markers such as CRP. Further studies may be re-
quired to clarify these speculations. In conclusion, we
hypothesize that the differential expression of VEGF and
HGF and up-regulation of the hypoxia-regulated master
gene HIF-1a in patients with DM versus patients without
DM may reflect more severe postsurgical complications in
patients with DM.
We acknowledge the genomics core facility at the Beth Israel
Deaconess Medical Center (www.bidmcgenomics.org) for their as-
sistance and expertise in the gene array analysis. Dr Manoj Bhasin
has performed the statistical analysis for the microarray data.
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